I do not "fiercely defend the share price performance" - in fact, I have rarely talked about the share price, other than in the context of the company's performance. My concern is, and has always been, the fundamentals of the company.
So I have no interest in explaining anything to those who ignore such vital factors and seek to latch onto anything that might shore up their cognitive biases.
Ann: New Family 4 Patent to be Granted for RECCE Anti-Infectives, page-26
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.030(5.26%) |
Mkt cap ! $122.3M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 62.0¢ | 56.5¢ | $158.1K | 263.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 77741 | 60.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 61.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| RCE (ASX) Chart |